Tags

Type your tag names separated by a space and hit enter

Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia.
J Antimicrob Chemother. 2011 Jul; 66(7):1617-24.JA

Abstract

BACKGROUND

A new category of healthcare-associated pneumonia (HCAP) has been added in the most recent American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines, since multidrug-resistant (MDR) pathogens are more common in patients with HCAP than in those with community-acquired pneumonia (CAP). The optimal empirical management of patients with HCAP remains controversial and adherence to guidelines is inconsistent.

METHODS

A retrospective cohort study of 3295 adults admitted for pneumonia in an academic centre of Canada, between 1997 and 2008.

RESULTS

MDR pathogens were more common among patients with HCAP than in those with CAP, but less so than in other studies. Compared with patients with CAP, those with HCAP had a higher all-cause 30 day mortality [68/563 (12%) versus 201/2732 (7%); P < 0.001] and more frequent need for mechanical ventilation [78/563 (14%) versus 276/2732 (10%); P = 0.01]. In patients with CAP, mortality was lower when treatment was concordant with guidelines [86/1557 (6%) versus 109/1097 (10%) if discordant; adjusted odds ratio 0.6 (0.4-0.8); P < 0.001]. In HCAP, mortality was similar whether or not empirical treatment was concordant with guidelines [6/35 (17%) versus 18/148 (12%) if discordant; P = 0.4]. However, 30 day mortality tended to be higher when the empirical treatment was microbiologically ineffective [4/22 (18%) versus 17/187 (9%) when effective; P = 0.3].

CONCLUSIONS

HCAP is associated with worse outcomes than CAP. MDR pathogens were implicated in only a small fraction of HCAP cases. In our study, unlike CAP, non-respect of current HCAP guidelines had no adverse effect on the ultimate outcome. Strategies for the empirical management of HCAP should be tailored to the local epidemiological context.

Authors+Show Affiliations

Department of Microbiology and Infectious Diseases, Université de Sherbrooke, Sherbrooke, Québec, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21586592

Citation

Grenier, Cynthia, et al. "Impact of Guideline-consistent Therapy On Outcome of Patients With Healthcare-associated and Community-acquired Pneumonia." The Journal of Antimicrobial Chemotherapy, vol. 66, no. 7, 2011, pp. 1617-24.
Grenier C, Pépin J, Nault V, et al. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. J Antimicrob Chemother. 2011;66(7):1617-24.
Grenier, C., Pépin, J., Nault, V., Howson, J., Fournier, X., Poirier, M. S., Cabana, J., Craig, C., Beaudoin, M., & Valiquette, L. (2011). Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. The Journal of Antimicrobial Chemotherapy, 66(7), 1617-24. https://doi.org/10.1093/jac/dkr176
Grenier C, et al. Impact of Guideline-consistent Therapy On Outcome of Patients With Healthcare-associated and Community-acquired Pneumonia. J Antimicrob Chemother. 2011;66(7):1617-24. PubMed PMID: 21586592.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. AU - Grenier,Cynthia, AU - Pépin,Jacques, AU - Nault,Vincent, AU - Howson,Jessika, AU - Fournier,Xavier, AU - Poirier,Marie-Sol, AU - Cabana,Jérôme, AU - Craig,Camille, AU - Beaudoin,Mathieu, AU - Valiquette,Louis, Y1 - 2011/05/17/ PY - 2011/5/19/entrez PY - 2011/5/19/pubmed PY - 2011/9/29/medline SP - 1617 EP - 24 JF - The Journal of antimicrobial chemotherapy JO - J Antimicrob Chemother VL - 66 IS - 7 N2 - BACKGROUND: A new category of healthcare-associated pneumonia (HCAP) has been added in the most recent American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines, since multidrug-resistant (MDR) pathogens are more common in patients with HCAP than in those with community-acquired pneumonia (CAP). The optimal empirical management of patients with HCAP remains controversial and adherence to guidelines is inconsistent. METHODS: A retrospective cohort study of 3295 adults admitted for pneumonia in an academic centre of Canada, between 1997 and 2008. RESULTS: MDR pathogens were more common among patients with HCAP than in those with CAP, but less so than in other studies. Compared with patients with CAP, those with HCAP had a higher all-cause 30 day mortality [68/563 (12%) versus 201/2732 (7%); P < 0.001] and more frequent need for mechanical ventilation [78/563 (14%) versus 276/2732 (10%); P = 0.01]. In patients with CAP, mortality was lower when treatment was concordant with guidelines [86/1557 (6%) versus 109/1097 (10%) if discordant; adjusted odds ratio 0.6 (0.4-0.8); P < 0.001]. In HCAP, mortality was similar whether or not empirical treatment was concordant with guidelines [6/35 (17%) versus 18/148 (12%) if discordant; P = 0.4]. However, 30 day mortality tended to be higher when the empirical treatment was microbiologically ineffective [4/22 (18%) versus 17/187 (9%) when effective; P = 0.3]. CONCLUSIONS: HCAP is associated with worse outcomes than CAP. MDR pathogens were implicated in only a small fraction of HCAP cases. In our study, unlike CAP, non-respect of current HCAP guidelines had no adverse effect on the ultimate outcome. Strategies for the empirical management of HCAP should be tailored to the local epidemiological context. SN - 1460-2091 UR - https://www.unboundmedicine.com/medline/citation/21586592/Impact_of_guideline_consistent_therapy_on_outcome_of_patients_with_healthcare_associated_and_community_acquired_pneumonia_ L2 - https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkr176 DB - PRIME DP - Unbound Medicine ER -